Pagrindai

Kraujas thinners are colloquially referred to as all drugs that interfere with blood clotting in various ways. However, the kraujas does not become thinner, it just coagulates more heavily. Clotting is an essential function of the kraujas and ensures that the bleeding is quickly stopped when injuries occur.

In some situations, however, a targeted inhibition of coagulation is desired, so that the use of blood thinners is useful here. The aim is therefore always to prevent the formation of a kraujo krešulys (thrombus), from which there are basically two dangers. One is acute vascular okliuzija, especially of arteries.

The other is the risk of thrombi being carried from veins and closing a vessel elsewhere. Blood thinners are currently taken by about XNUMX million people in Germany on a permanent basis and by many more for short periods of time, e.g. after a medical intervention. Within blood thinners, one can differentiate between different active substances with different mechanisms and areas of application. Blood thinners are mainly used prophylactically to prevent dreaded complications in certain diseases, but also acutely, for example in the case of a širdis attack, to inhibit the growth of the kraujo krešulys that has formed. Medical terms for blood thinners are anticoagulants or thrombocyte aggregation inhibitors.

Veikimo

In order to understand the mechanism of action of blood thinners, it is necessary to briefly consider the coagulation system of the blood in a simplified form. It can be activated by injuries, disturbances of the blood flow in the laivai and pre-damaged vessel walls. Arteriosklerozė, i.e. the calcification of laivai, plays a major role in this process.

kraujo krešėjimo can be divided into two parts. First, the blood trombocitai (thrombocytes) play the main role. They are activated when required by certain signals, attach themselves to the vessel wall and stick together.

By releasing messenger substances, they activate further trombocitai, which expand the network. This leads to the first kraujo krešulys (white thrombus), which is intended to provide a temporary cover for the leak. Certain receptors and messenger substances play a decisive role in the activation and adhesion.

A main group of blood thinners, known as platelet aggregation inhibitors, act on these receptors and messengers. The name reveals that these blood thinners inhibit the attachment and adhesion of the blood trombocitai and thus prevent the formation of the clot. The best known blood thinner of this type is acetylsalicylic acid, better known as ASA or aspirinas. It prevents the formation of an important messenger substance to activate the blood platelets. Also widely used is klopidogrelis, which blocks a receptor on the surface of the blood platelets so that it cannot be activated.

Secondary/plasmatic coagulation

The other part of blood clotting is carried by certain baltymai in the blood, the clotting factors. This is somewhat slower, but ensures better cross-linking and forms a more stable red thrombus. The blood thinners that intervene here work on a total of XNUMX coagulation factors.

The best-known and most widely used agent in this context is Marcumar® . It is a vitamin K antagonist which inhibits the formation of four coagulation factors – factors XNUMX and XNUMX – and thus effectively suppresses the system. Another agent with the same mechanism is warfarin.

For several years now, other blood thinners have been on the market that intervene in plasmatic coagulation elsewhere. These are direct inhibitors of a coagulation factor: Dabigatran, which blocks Factor XNUMX, and Rivaroxaban, an inhibitor of Factor XNUMX. In addition, there is heparinas, which is also often used, but is only used for a short period of time for the treatment of vascular okliuzija or as a prophylactic against it.

It works by increasing the effectiveness of a protein (antithrombin XNUMX) in the body by a factor of XNUMX, which controls the coagulation. The complex of antithrombin XNUMX and heparinas is thus a competent anticoagulant. Which of the above-mentioned agents is used as a blood thinner depends on the indication and the individual situation of the patient.

Susiję straipsniai:

Klavulano rūgštis

Produktai Klavulano rūgštis parduodama tik kartu su antibiotiku amoksicilinu. Be originalaus „Augmentin“, taip pat yra daugybė generinių vaistų. Struktūra ir savybės Klavulano rūgšties (C8H9NO5, Mr = 199.16 g / mol) yra vaistuose kaip kalio klavulanatą, klavulano rūgšties kalio druską. Kalio klavulanatas yra baltas,

Skaityti daugiau "

Organinis ir neorganinis magnis

Apibrėžimas Magnio yra vaistiniuose produktuose ir maisto papilduose druskų su priešionu pavidalu: Mg2 + + Neigiamai įkrautas priešionas. Organinėse magnio druskose priešionas yra organinis, tai yra, jame yra anglies ir vandenilio atomų: organinių magnio druskų (pasirinkimas): magnio aspartatas, magnio citratas, magnio gliukonatas, magnis

Skaityti daugiau "

„Efmoroctocog Alfa“

Produktai Efmoroctocog alfa buvo patvirtintas daugelyje šalių 2016 m. Kaip milteliai ir tirpiklis injekciniam tirpalui paruošti (Elocta). Struktūra ir savybės Efmoroktokogas alfa yra rekombinantinis sulietas baltymas, susidedantis iš žmogaus VIII krešėjimo faktoriaus be B domeno, kovalentiškai prisijungusio prie Fc domeno

Skaityti daugiau "

Dimetindeno maleato gelis

Produktai Dimetindeno maleatas yra komerciškai prieinamas daugelyje šalių nuo 1974 m. Gelio pavidalu (Fenistil gelis). Struktūra ir savybės Dimetindeno (C20H24N2, Mr = 292.4 g / mol) vaistuose yra kaip dimetindeno maleatą - baltus kristalinius miltelius, kurie blogai tirpsta vandenyje. Pavadinimas kilęs

Skaityti daugiau "

Apyniai: programos, gydymas, nauda sveikatai

Už šnekamojo apynių pavadinimo yra aromatinis augalas, botaniškai tiksliai vadinamas tikruoju apyniu arba Humulus lupulus. Apynių atsiradimas ir auginimas Apynių vaisiniuose stiebuose yra daugybė svarbių sveikatai ingredientų. Apyniai išgarsėjo daugiausia dėl to, kad šis augalas yra pagrindas

Skaityti daugiau "

Levosimendanas

Produktai „Levosimendan“ yra parduodamas kaip koncentratas infuziniam tirpalui paruošti („Simdax“). Daugelyje šalių jis buvo patvirtintas 2013 m. Struktūra ir savybės Levosimendanas (C14H12N6O, Mr = 280.3 g / mol) Poveikis Levosimendanas (ATC C01CX08) turi teigiamų inotropinių ir kraujagysles plečiančių savybių. Poveikis atsiranda dėl susiejimo su

Skaityti daugiau "
Sveikatos faktai